Imed Infinity Medical-Limited Partnership
IMED.TA
Tel Aviv Stock Exchange127.00
ILA
+4.10
- -
ISIN
IL0011712309
Return %
Stock
S&P500
1Y
11.31
26.53
3Y
4.10
76.60
5Y
-82.06
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Itay Gal-Or
- Full Time Employees
- 70
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- Azrieli Tower Tel Aviv Israel 6701101
- IPO Date
- Jan 4, 2021
- Website
- infinitymedical.co.il
- Similar Companies
- Business
- Imed Infinity Medical-Limited Partnership (IMED.TA) operates as a research and development partnership focused on investing in and advancing digital health technologies, primarily through stakes in innovative startups targeting the Chinese and global markets; its core portfolio encompasses AI-driven genetic analysis platforms from Genoox, wireless vital signs monitoring devices including wrist and chest monitors from Biobeat, quantum computing-enabled drug design software from POLARISqb, IoT cybersecurity solutions for medical devices from Cynerio, neuromodulation-based migraine relief patches such as Nerivio from Theranica, AI-powered human body modeling for drug prediction from CytoReason, and portable electrospinning wound healing systems from Nanomedic. The partnership, founded in 2020 and headquartered at Azrieli Center in Tel Aviv, Israel, supports these companies in transitioning from development to commercialization, leveraging expertise in medicine, technology, business, and finance, with a strategic emphasis on cross-border expansion into China via affiliations with the Infinity Group. Geographically, it maintains operations centered in Israel with portfolio reach into the US, Europe, and Asia, serving hospitals, pharmaceutical firms, and healthcare providers. Recent developments include ongoing portfolio growth and investments, such as a $750,000 commitment to Nanomedic's wound care technology, amid stable public listing on the Tel Aviv Stock Exchange since December 2020 and positive earnings of approximately ILS 890,000 on ILS 2.69 million revenue as of late 2025.